{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-032662","form_type":"8-K","ticker":"PHIO","cik":"0001533040","company_name":"Phio Pharmaceuticals Corp.","filed_at":"2025-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.664438+00:00","generated_at":"2026-05-17T00:52:03.725285+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Phio Pharma: INTASYL PH-762 shows 100% tumor clearance in one cSCC patient; SMC clearance safe","bullets":["100% pathologic complete response in 1 of 3 cSCC patients at Day 36 in final dose cohort; >90% clearance in second, >50% in third.","Safety Monitoring Committee issued favorable review, no dose-limiting toxicities at max dose; PH-762 well tolerated across 5 cohorts.","Cumulative Phase 1b data: 6 complete, 2 near-complete, 2 partial responses among 16 cSCC patients; no clinical progression.","CEO notes PH-762 is promising non-surgical alternative for cutaneous carcinomas; trial continues to screen additional patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-032662","json":"https://secwatch.observer/filing/0001437749-25-032662.json","markdown":"https://secwatch.observer/filing/0001437749-25-032662.md","text":"https://secwatch.observer/filing/0001437749-25-032662.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533040/000143774925032662/0001437749-25-032662-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533040/000143774925032662/phio20251023_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:52:03.725285+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}